{"id":48535,"date":"2022-09-19T14:03:00","date_gmt":"2022-09-19T12:03:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/"},"modified":"2022-09-19T14:03:00","modified_gmt":"2022-09-19T12:03:00","slug":"large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/","title":{"rendered":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference<\/a> taking place in Boston.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry<\/a>, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.\n<\/p>\n

\n\u201cThe results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,\u201d said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.\n<\/p>\n

\nThese results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study<\/a> (NCSI) and the Inova study by Tehrani et al<\/a>., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1<\/i>).\n<\/p>\n

\nJ-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).\n<\/p>\n

\nABOUT IMPELLA HEART PUMPS<\/b>\n<\/p>\n

\nImpella 2.5, Impella CP\u00ae, Impella CP with SmartAssist, Impella 5.0\u00ae, Impella LD\u00ae, and Impella 5.5\u00ae with SmartAssist\u00ae are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.\n<\/p>\n

\nABOUT ABIOMED<\/b>\n<\/p>\n

\nBased in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and\/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http:\/\/www.abiomed.com<\/a>.\n<\/p>\n

\nFORWARD-LOOKING STATEMENTS<\/b>\n<\/p>\n

\nAny forward-looking statements are subject to risks and uncertainties such as those described in Abiomed’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information:<\/b>
Media:<\/b>
Jenny Leary
\n
Associate Director, U.S. Communications
\n
+1 (978) 882-8491
\n
jleary@abiomed.com<\/a>\n<\/p>\n

\nInvestor:<\/b>
Todd Trapp
\n
Executive Vice President and Chief Financial Officer
\n
+1 (978) 646-1680
\n
ttrapp@abiomed.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48535","6":"format-standard","7":"category-industry"},"yoast_head":"\nLarge, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-19T12:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%\",\"datePublished\":\"2022-09-19T12:03:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005279\\\/en\\\/1575261\\\/21\\\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/\",\"name\":\"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005279\\\/en\\\/1575261\\\/21\\\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg\",\"datePublished\":\"2022-09-19T12:03:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005279\\\/en\\\/1575261\\\/21\\\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005279\\\/en\\\/1575261\\\/21\\\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/","og_locale":"en_US","og_type":"article","og_title":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-19T12:03:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%","datePublished":"2022-09-19T12:03:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/"},"wordCount":404,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/","url":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/","name":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg","datePublished":"2022-09-19T12:03:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220919005279\/en\/1575261\/21\/Improved_Survival_and_Native_Heart_Recovery_Sept._2022_Adding_JPVAD.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/large-multi-center-multi-society-study-of-impella-supported-patients-finds-30-day-ami-cardiogenic-shock-survival-of-81\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48535"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48535\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}